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doi:10.1016/j.ejvs.2010.01.022Abstract Objectives: The aim of this study was to compare the efficacy and side effects of
ultrasound-guided foam sclerotherapy of the great saphenous vein using 1% and 3% polidocanol
foam with a 3-year follow-up.
Design: A multicentre prospective double-blind randomised clinical trial comparing the effi-
cacy of 1% vs. 3% polidocanol sclerosant foam.
Materials and methods: Patients with incompetence of the great saphenous vein (GSV) in
CEAP clinical classes C2e5 (CEAP, ClinicaleEtiologyeAnatomyePathophysiology), with or
without incompetence of the sapheno-femoral junction, were included. The Turbofoam
method was used to create 1% and 3% polidocanol foam, which was injected into the GSV
under ultrasound guidance, with a volume not exceeding 10 ml. Further foam sclerotherapy
was carried out at 6 weeks, 3 and 6 months if required to abolish persistent venous reflux. The
main outcome measure was the absence of saphenous reflux as assessed by ultrasound
imaging at 6 months, 1, 2 and 3 years. Clinical severity (Venous Clinical Severity score (VCSS))
and quality of life (the Chronic Venous Insufficiency Questionnaire (CIVIQ)) scores were as-
sessed.
Results: A total of 143 patients were included; 1% group men Z 18, women Z 55, 3% group
menZ 19, womenZ 51. The abolition of venous reflux was: 1% group, 69% and 3% group, 85%
at 6 months; 1% group, 79% and 3% group, 78% at 3 years (including additional injections at 6
months). Three asymptomatic thrombo-embolic events (2%) occurred. Local side effects76 76 53 61; fax: þ33 4 76 76 50 48.
ble.fr (J.L. Bosson).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
780 S. Blaise et al.(principally pigmentation and matting) were 9% in the 3% group and 6% in the 1% group at 3
years (N.S.). Clinical severity and quality of life scores improved by more than 20% at 6
months in both the groups, with no difference between the groups.
Conclusions: This is the first randomised clinical trial of ultrasound-guided foam sclerother-
apy which is a 3-year follow-up and shows equivalent efficacy of 1% and 3% sclerosant foam.
Clinical trial registration number: 2006-07-05.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Foamed sclerosant drugs are effective in the management
of incompetent saphenous veins. Although it is recognised
that foamed sclerosants are superior in efficacy to liquid
sclerosants, the technique has not yet been standardised
and there are wide variations in clinical practice, both in
the concentrations used and in the volumes of foam
injected. While the initial studies employed foam concen-
trations of 3%, the maximum concentration that can be
used, some preliminary studies have demonstrated that the
lower concentrations may have similar efficacy. Further-
more, few studies have been published concerning the
long-term outcome of this treatment.
Study objectives
The aim of the study was to assess the efficacy and toler-
ance of sclerotherapy with 1% and 3% polidocanol foam in
the treatment of great saphenous vein (GSV) incompe-
tence. The primary objective was the efficacy of abolition
of venous reflux at 6 months. The main outcome measure
was the abolition of venous reflux in the GSV at 6 months
assessed by colour duplex ultrasonography (absence of
saphenous reflux in the thigh lasting more than 1 s).
Secondary objectives concerned the clinical outcome
and ultrasound assessment of saphenous vein obliteration
at 3 years, as well as tolerance of the treatment. The
secondary outcomes included clinical evaluation using the
Venous Clinical Severity score (VCSS), the quality of-life
score using the Chronic Venous Insufficiency Questionnaire
(CIVIQ) both at 6 months and 3 years, and absence reflux in
the GSV at 3 years. Tolerance to treatment was assessed
from local and systemic side effects, which occurred
immediately and after 6 months and 3 years of follow-up.
Materials and methods
This was a multicentre prospective randomised, double-
blind clinical trial with two arms and no placebo group,
with direct benefit to the patient. Patients considered for
inclusion in this trial had primary incompetence of the GSV
with or without incompetence of the sapheno-femoral
junction. Details of the inclusion and exclusion criteria
are presented in Table 1. The study was approved on 12
November 2003 by the South East France regional ethics
committee (registration number 03/ARMV/1) and conforms
to the Helsinki declaration (1964, version Hong Kong, 1989).
All the patients were given a copy of the written study
information document approved by the Ethics Committee
and gave written informed consent before inclusion in the
trial. The clinical trial registration number is 2006-07-05.The sclerosant drug used was polidocanol (Kreussler
Pharma, Wiesbaden, Germany) and patients were rando-
mised to receive a concentration of 1% or 3% (Fig. 1). The
randomisation was centralised and coordinated by
a computer system. Randomisation and the management of
the stocks for double-blind use were performed by the
Clinical Research Centre in collaboration with Kreussler
Pharma who supplied the ampoules of polidocanol without
commercial labels. The randomisation list was computer
centralised, without stratification, equilibrated and with
blocks of variable size. Envelopes were distributed to the
investigating centres with numbers corresponding to the
sclerosant lots. Double blinding was thus maintained for all
the injections and until the end of patient follow-up (3
years in total).
Sclerosant foam was obtained using a Turbofoam
system (Kreussler Pharma, Wiesbaden, Germany). The
sclerosant liquid was mixed with sterile air to obtain
a liquid-to-air ratio of 1:5. The foam was injected imme-
diately after production or within 170 s.
Nine investigation centres were selected with investi-
gating physicians who were experienced in the practice of
ultrasound-guided sclerotherapy. They had personally per-
formed at least 300 sclerotherapy procedures during the
previous 3 years. In addition, each investigating physician
was trained in the study procedure. The colour Doppler
ultrasound apparatus used had to be fitted with a high-
resolution probe with an imaging frequency of 7.5 MHz or
higher and a system for the reproduction and/or storage of
images.
The initial treatment consisted of placing a short intra-
venous catheter (20-G 1.1  48 mm or butterfly 22-G
0.9  22 mm) in the lower third of the GSV in the thigh
under ultrasound guidance. In this region, the GSV is at its
closest to the fascia superficialis. The treatment was
performed under ultrasound control with gel and sterile
gloves. The volume of foam to be injected was estimated
from the quantity that produced venous spasm, but did not
exceed 10 ml. Compression of 34e49 mmHg was achieved
by applying an adhesive foam bandage (Elastomousse,
BSNmedical, Le Mans, France) and followed by a further
layer of Elastoplast (BSNmedical, Le Mans, France).
Bandages were applied immediately after the treatment to
be worn continuously for 3 days. They were then removed
and a class 2 elastic compression stocking (Oedema Twin
25, Kreussler Pharma, Wiesbaden, Germany; 23e32-mmHg
compression) was worn during the day for 15 days.
During the follow-up period, patients were assessed
clinically and by duplex ultrasound imaging at 8 days, 6
weeks, 3 months, 6 months, 1 year, 2 years and 3 years.
Further ultrasound-guided foam sclerotherapy was allowed
Table 1 Inclusion and exclusion criteria for the study patients.
Inclusion criteria Exclusion criteria
Age between 25 and 75 years.
Incompetence of the great
saphenous vein on Doppler
ultrasound (reflux > 1 s).
Classification CEAP C2, C3, C4, C5.
Ep As 2-3 Pr
Maximum diameter of great saphenous vein at the thigh
(supine position) 8 mm.
Giving of written informed consent.
Post-thrombotic disease.
Incompetence of the small saphenous vein
or a non saphenous vein (CEAP: A4-5).
Classification CEAP: C0, C1 or C6.
Recurrent varicose of the great saphenous
vein after stripping.
Known thrombophilia or a history of thrombo-embolic disease.
Psychiatric disorders.
Known allergy to polidocanol or to one of its constituents.
Arterial disease of the lower limbs (IPS<0.8).
Post-phlebitic disease.
Chronic liver disease.
Renal failure (creatine > 150 micromol/l).
Pregnancy or breast feeding.
Women without effective contraception with risk of pregnancy.
Progressing malignancy.
Uncontrolled hypertension.
Cardiac or respiratory insufficiency.
Intolerance to alcohol acquired or induced by a treatment.
History of migraine, particularly ophthalmic
1% vs. 3% POL Foam Sclerotherapy of the GSV 781by the protocol at 6 weeks, 3 and 6 months. The investi-
gators performed both sclerotherapy and vascular sonog-
raphy. During these additional sclerotherapy sessions,
a volume of up to 4 ml of foam was allowed to be injectedAllocated to treatment A 




72 at 6 week visit 
 17 with additional injection 
72 at 3 month visit 
 10 with additional injection 
Analyzed at 6 months for 
principal criteria 
N=72
 22 with additional injection 
68 at 1 year visit 
66 at 2 year visit 
67 at 3 year visit 
Figure 1 Studyinto veins with a persistent lumen of at least 2 mm in
diameter and 50 mm in length. A re-canalised vein without
the presence of venous reflux or with reflux lasting less than
1 s was not considered a failure and was not re-injected.Allocated to treatment B 
(3% polidocanol foam) 
N=70
ents 
68 at 6 week visit 
 8 with additional injection 
68 at 3 month visit 
 8 with additional injection 
Analyzed at 6 months for 
principal criteria 
N=68 
 13 with additional injection 
66 at 1 year visit 
66 at 2 year visit 
64 at 3 year visit 
Flow Chart.
Table 2 Baseline characteristics of the treated population.
Baseline characteristics 1% N Z 73 3% N Z 70 Study population N Z 143
Age, mean (SD) 53 (13) 52 (14) 52 (13)
Men, n (%) 18 (25%) 19 (27%) 37 (26%)
Right side, n (%) 35 (48%) 42 (60%) 77 (54%)
VCSS score, mean (SD) 4.5 (1.6) 4.4 (2.2) 4.5 (1.9)
CIVIQ test, mean (SD) 32 (9.4) 31 (9.3) 31 (9.3)
Type of incompetence, n (%)
Total sapheno-femoral junction incompetence 45 (62%) 39 (56%) 84 (59%)
Partial sapheno-femoral junction incompetence 2 (3%) 4 (6%) 6 (4%)
Pre-terminal valve incompetence 20 (27%) 25 (36%) 45 (31%)
Trunk vein incompetence 5 (7%) 2 (3%) 7 (5%)
Perforating vein of the thigh 1 (1%) 0 (0%) 1 (1%)
Diameter of the GSV, mean (þ/SD)
Maximum diameter, mm 6.1 (1.6)a 6.6 (1.7)a 6.4 (1.7)a
Mean diameter, mm 4.7 (1.4)b 5 (1.1)b 4.9 (1.3)b
VCSS Z Venous Clinical Severity Score; CIVIQ 2 Z a French Quality of Life questionnaire.
a 5 missing for the maximum diameter (5 in the 1% group and 0 in the 3% group).
b 6 missing for the mean diameter (4 in the 1% group and 2 in the 3% group).
782 S. Blaise et al.The investigator and patient remained blinded to the
treatment that was administered throughout the 3-year
study period. In the event of a side effect (including
thrombo-embolic events), there was no need for unblinding
as knowledge of the concentration used would in no respect
change what is to be done.
Systematic clinical and ultrasound surveillance were
performed at 8 days, 6 weeks, 3 months, 6 months, 1 year,
2 years and 3 years. At 8 days, a duplex ultrasound inves-
tigation was performed. Three views were taken: theTable 3 Local side effects (6 months and 3 years) and thrombo
Local complication 1%
6 months, n (%) N Z 72
pain > Z 1 5 (7%)
superficial thrombosis 3 (4%)
pigmentation 14 (19%)
cutaneous inflammation 3 (4%)
Matting 4 (6%)
induration 2 (3%)
at least 1 complication 15 (21%)
N Z 67
3 years, n (%)






at least 1 complication 4 (6%)
1%
Thromboembolic- complications 2 (3%)
details:
Proximal thrombosis 1 (1%)
Distal perforator thrombosis 1 (1%)
Distal muscle vein thrombosis 0sapheno-femoral junction and the sural veins, with and
without compression. The following items were noted:
obliteration or not flush with the sapheno-femoral junc-
tion, persistence of patent collaterals, persistence of
a venous stump and its length and whether any reflux
persisted. Each segment of the GSV was studied (the
proximal, middle and distal portions) noting whether
obliteration had been achieved or not, and whether this
was complete or not, its diameter, the presence of reflux

















6 (9%) NS 0.463
3% together




1% vs. 3% POL Foam Sclerotherapy of the GSV 783had to be systematically documented by photography. At
the other visits (6 weeks, 3 months, 6 months, 1 year, 2
years and 3 years), clinical examination was performed,
the ClinicaleEtiologyeAnatomyePathophysiology (CEAP)
score determined and observations regarding pain, super-
ficial thrombosis, pigmentation, cutaneous inflammation,
matting and induration had to be systematically recorded
(Table 3).
A critical events committee made up of three non-
investigator physicians classified the adverse events with
respect to the treatment received. Every reported event
was examined by the committee. Events were classified as
expected local side effects or systemic (visual symptoms,
etc.) and serious adverse events (deep vein thrombosis,
pulmonary embolism, stroke, etc.). Following consultation
of the patient’s medical records, the committee decided on
the imputability. Patients completed the VCSS and CIVIQ
questionnaires of quality of life at inclusion, 6 months, 1
year, 2 and 3 years.2,3
Sample size
The initial hypothesis assumed 90% success for the main
outcome measure (abolition of reflux) in the two groups.
The definition of therapeutic equivalence was with
a d value of 10%. A one-sided test was used with an a risk ofChange in VCSS score with time
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Figure 2 Changes in VCSS and CIVIQ scores between inclu-
sion and 3 year visit for the two treated groups.0.05 and b risk of 0.10. We obtained a sample size of 150
patients using the nQuery Advisor program version 7.0.Statistical methods
The statistical analysis was performed on an intention-to-
treat basis. Categorical variables are expressed as
frequencies and percentages, and continuous variables as
the mean and standard deviation. The principal outcome
and efficacy at 6 months and 3 years were tested using a test
of equivalence by the HauckeAnderson method. Secondary
outcomes were tested by a chi-square test without correc-
tion for continuity for the qualitative variables and by
a Student’s t-test for the continuous variables. An analysis
of variance (ANOVA) for repeated measurements was also
performed (comparison M0/M6/1y/2y/3y). The statistical
tests used a type 1 error of aZ 0.05. Statistical analysis was
performed using Stata (version 10.0; Stata Corp, College
Station, TX, USA). The equivalence tests were performed
with Equiv Test (Statistical Solutions).Results
Between March 2004 and May 2005, 143 patients were
included (Fig. 1). At 3 years, 3.5% were lost to follow-up.
Table 2 gives the characteristics of the population. The
abolition of significant reflux in the GSV was 69% for 1%
foam and 85% for 3% foam at 6 months and 82% for 1% foam
and 90% for 3% foam at 1 year (including the additional
injection at 6 months) and 79% for 1% foam and 78% for 3%
foam at 3 years. The results are equivalent at 3 years
(p Z 0.05).
The volumes of foam injected initially were a mean of
6.1 ml for the 1% group and 6.4 ml for the 3% group. At least
one additional injection was required for 49% of patients in
the 1% group and 31% in the 3% group, which is a significant
difference (pZ 0.04). The percentage of patients requiring
an additional injection in the 1% and 3% groups, respec-
tively, was 24% and 12% at 6 weeks, 14% and 12% at 3
months and 31% and 19% at 6 months. The presence or
absence of sapheno-femoral junction incompetence did not
influence the efficacy of treatment.
The clinical severity scores assessed by VCSS and of
quality of-life measured by the CIVIQ questionnaire
improved following the initial treatment session (Fig. 2),
with a reduction of more than 20% in the scores in each
group after 6 months and no significant difference between
the two groups.
At 3 years, local side effects were 9% in the 3% group and
6% in the 1% group (pZ 0.46) (Table 3). Patients who had at
least one local complication at 6 months had a VCSS score
that was significantly higher compared to those with no
complication (p < 0.01). By contrast, the CIVIQ test score is
similar (p Z 0.73). At 3 years, there is no significant
difference for either test.
Three thrombo-embolic events (2%) were reported, two
of which were in the 1% group. Three cases of asymptom-
atic deep vein thrombosis were detected at day 8 and no
patient suffered pulmonary embolism: one proximal
thrombosis (femoral vein), one thrombosis of a distal
784 S. Blaise et al.perforating vein associated with a muscle vein thrombosis
(soleal vein) and one distal muscle vein thrombosis (medial
gastrocnemius vein).
In all the three cases, tests revealed associated throm-
bophilia (one heterozygous mutation of factor V Leiden
gene mutation, one heterozygous prothrombin gene muta-
tion and one of acquired anti-thrombin III deficiency). After
anticoagulant treatment for 6 weeks, the thrombi
completely disappeared in all three cases. No case of
migraine or other neurological event occurred during the
study.Discussion
Several studies have shown that foamed sclerosant drugs are
more effective in obliterating saphenous trunks than liquid
sclerosants.4e7 Foam sclerotherapy has revolutionised the
practice of sclerotherapy, permitting effective obliteration
of saphenous trunks as well as varices. There is great vari-
ation in the way in which this technique is used in clinical
practice. Many variations in technique have not been eval-
uated as to their influence on the final outcome. The meta-
analysis published by Jia gives poorer results for foam scle-
rotherapy compared to surgery (relative risk 0.86).8 Never-
theless, she points out that there are many limitations in the
methods used for comparing the techniques.
An important factor in determining the outcome is the
experience of the physician performing the treatment
and the method he uses. This is demonstrated in the
study by Wright et al. when assessing the efficacy of
Varisolve,9 which is a microfoam containing a 1%
aqueous solution of polidocanol incorporating oxygen and
carbon dioxide to create a foam. It may not be strictly
comparable to polidocanol foam made using the Turbo-
foam method of our study. Excellent efficacy was
reported in the patient group treated by a phlebologist
experienced in sclerotherapy (94%) but was considerably
lower when performed by a surgeon (68%).4,6 In our
study, we minimised this bias by ensuring all investigating
physicians were experienced sclerotherapists.
Other variables, such as the type and concentration of
the sclerosant drug, the type of gas, the liquid/gas ratio,
the method of foam preparation (temperature and pH),
the time needed for foam preparation and use and
bubble size, could influence the efficacy. To improve
foam quality, techniques have been developed.10 In our
study, the foam was produced in an automated manner
with a Turbofoam apparatus to be as reproducible and
homogeneous as possible.11 The aim of the study was
focussed on the quantity of sclerosant injected, which
can vary in two parameters: the volume injected and the
concentration used.
Patients included in this study had incompetence of the
GSV with or without incompetence at the sapheno-femoral
junction. The efficacy of sclerosant foam treatment for
saphenous trunk incompetence that includes the sapheno-
femoral junction has been reported previously.12,13 We
chose to limit the diameter of the GSV in this study to
8 mm and to exclude affected perforating or small
saphenous veins so as to make the characteristics of the
treated veins as homogeneous as possible. The volume offoam injected was defined as the volume that produced
venous spasm. Hamel-Desnos reported a positive predictive
value of 100% for this criterion in predicting abolition of
reflux in the sclerosed vein.13 The latest European
consensus on sclerotherapy with foam has questioned the
appropriateness of this predictive value: it does not appear
to be a good indicator of the long-term outcome.14 We used
this criterion to indicate when sufficient foam had been
injected, and limited the maximum volume to 10 ml per
injection session, a volume in agreement with the recom-
mendations of several consensus reports.15,16 Using this
strategy, we consider that we performed a double-blind
randomised trial that included assessment of the injected
volume required at each concentration, whilst limiting
biases associated with foam production and operator-
dependent factors.
We found equivalence of outcome in the 1% and 3%
treatment groups at 3 years, although at 6 months the
outcome appeared to be slightly less successful in the 1%
group. The improvement for the 1% group at 3 years could
possibly be explained by additional at 6 months where
venous reflux persisted. There was no significant difference
in efficacy whether the sapheno-femoral junction was
competent or not and whatever the treatment group was.
The volumes injected at inclusion in the two groups were
similar. To our knowledge, this is the only double-blind study
to assess the efficacy of foam with a follow-up at 3 years. In
a prospective double-blind study of 80 patients, Ceulen
concluded that sclerosant foam at 3% (80%) was more
effective than 1% foam (70%) at 1 year.17 In a comparative
study, Hamel-Desnos shows an efficacy at 68% with 1% and
69% with 3% sclerosant foams at 2 years.1 In this study,
venous spasm was the criterion defining the volume of
sclerosant to be injected. The first injection consisted of
a volume of 2.5 ml to be repeated a maximum of three
times, depending on the occurrence of a spasm. Efficacy
was assessed at up to 2 years but without the possibility of
additional injections, in contrast to our procedure.1 Similar
efficacy was observed in the two treatment groups, the
mean volume injected was similar (4.4 ml in the 3% group
and 4.6 ml in the 1% group). Our study provides additional
information on the longer-term results compared to these
studies. It suggests equivalent efficacy between 1% and 3%
at medium term, with fewer injections for the 3% group.
Quality of life has been assessed in few studies of foam
sclerotherapy. Some studies have included legs, and not
patients, irrespective of the functional improvement to the
patient.18 Furthermore, the scales used for evaluation are
not always specified.12 We have assessed the functional
improvement achieved by foam sclerotherapy, which is
already apparent 6 months after treatment in both the
groups. The scales we have used were the VCSS2 and the
CIVIQ test, a French quality of life questionnaire for patients
with chronic lower limb venous insufficiency.3 In our study,
we found significant correlation between patients having at
least one local complication at 6 months and a higher VCSS
score compared to those having no complication. No such
correlation was found for the quality of life.
The local and systemic side effects of sclerosant foam
are well known. However, there is disagreement in the
literature regarding any link between the concentration or
the volume of foam and local side effects. Some authors
1% vs. 3% POL Foam Sclerotherapy of the GSV 785consider that local side effects are related to the volume of
foam injected12 but this does not seem to be the case in our
study. In the study by Ceulen, pigmentation was more
frequent in the 3% group (18% vs. 8.1%) for similar total
volumes injected in the two groups (5.3 ml for the 1% group
vs. 5.1 ml for the 3% group).17 The side effects appear to be
more closely linked to the concentration used rather than
to the volume injected. The results of our study are
consistent with this, with similar volumes resulting in more
pigmentation at 3 years in the 3% group.
The general complications of this technique are the
same as those for conventional sclerotherapy. Limited data
are available in the literature on the rate of complications
as a function of concentration used. The passage of scle-
rosant foam into deep veins is less when small volumes of
foam are used.19 The occurrence of complications varies
depending on the studies considered. Jia undertook a meta-
analysis of 69 studies of treatment by sclerotherapy for
venous insufficiency.8 Serious side effects are estimated to
be between 0% and 5.7%, with one case of pulmonary
embolism in a series of 1316 patients treated and
a percentage of deep vein thrombosis of between 0.1% and
18%.20,21 The disadvantages are mainly characterised by the
occurrence of venous thrombo-embolic reactions due to
undiagnosed thrombophilia, as in our study. It should be
noted that no neurological event that could be attributed
to the possible presence of a foramen ovale was reported
during our study.14
Our study shows equivalent efficacy of 1% and 3%
sclerosant foam used to treat truncal incompetence of the
GSV as assessed by ultrasound imaging and by clinical
severity score and the CIVIQ quality- of-life questionnaire.
The trial concerned only treatment of GSV reflux and
excluded other associated conditions such as the perfo-
rating or small saphenous veins that are encountered in
clinical practice. The protocol allowed additional injec-
tions if necessary, to reflect clinical practice, while at the
same time limiting bias. The assessment of the efficacy of
sclerotherapy used a completely different approach to
that of other vein ablation treatments, such as surgery,
radiofrequencies or laser, which usually require a single
treatment session. From the scientific point of view, this
makes sclerotherapy more difficult to compare with the
other techniques.Funding
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